Owkin Stock

owkin.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $279.77MM

Owkin is an AI biotech company using federated learning to connect biopharma companies and medical partners. Owkin's technology unlocks insights from siloed datasets that allow for the development of precise medical approaches to the treatment of disease. Owkin was founded in 2016 by Dr. Thomas Clozel and Dr. Gilles Wainrib and is headquartered in New York, NY.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Owkin, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

Owkin Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Owkin Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
06/08/2022 Series B-1 $50MM $xx.xx $1.46B Bristol Myers Squibb
Price per Share
$xx.xx
Shares Outstanding
1,094,169
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bristol Myers Squibb
11/18/2021 Series B $155.04MM $xx.xx $1.29B Sanofi
Price per Share
$xx.xx
Shares Outstanding
3,602,182
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sanofi
05/07/2020 Series A-3 $43.55MM $xx.xx $252.21MM Bpifrance Large Venture, Cathay Innovation, MACSF, GV, F-Prime Capital, Eight Roads Ventures
Price per Share
$xx.xx
Shares Outstanding
4,860,488
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bpifrance Large Venture, Cathay Innovation, MACSF, GV, F-Prime Capital, Eight Roads Ventures
03/07/2019 Series A-2 $13.04MM $xx.xx $113.97MM F-Prime Capital, Eight Roads Ventures, GV, Cathay Innovation, NJF Capital
Price per Share
$xx.xx
Shares Outstanding
2,502,208
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
F-Prime Capital, Eight Roads Ventures, GV, Cathay Innovation, NJF Capital
05/24/2018 Series A $16.02MM $xx.xx $51.43MM GV, Otium Venture, Cathay Innovation, Plug and Play Ventures, NJF Capital
Price per Share
$xx.xx
Shares Outstanding
5,936,265
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GV, Otium Venture, Cathay Innovation, Plug and Play Ventures, NJF Capital
05/01/2017 Series Seed $2.12MM $xx.xx $7.06MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,589,861
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors

Owkin investors also invested in these private companies

Leadership & Board

Leadership

Hubert Chaperon
Chief Operating Officer
Darius Meadon
Chief Marketing Officer
Gilles Wainrib Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Meriem Sefta Ph.D
Chief Diagnostics Officer & Chief Data and Clinical Solution Officer
Alban Sablière
Chief Business Officer
Jean-Philippe Vert
Chief Research and Development Officer
Jean-Frédéric Petit-Nivard
Chief Commercial Officer
Thomas Clozel MD
Co-Founder, Chief Executive Officer & Board Member
Mathieu Galtier Ph.D
Chief Data and Platform Officer
Vassili Soumelis
Chief Medical Officer
Andreas Emmenegger
Chief Financial Officer
Anna Huyghues-Despointes
Chief Corporate Development Officer
David Cahane
Chief Solutions Officer
Mariabrisa Olivares
Chief People Officer
Leo Cunningham
Chief Information Security Officer

Board

Jacky Abitbol
Cathay Innovation
Laurent Higueret, PharmD
Bpifrance
Alex Pasteur
F-Prime Capital
Bruno Raillard
FRST Capital
Nicole Junkermann
NJF Holdings

Owkin stock FAQs

plusminus

Can you buy Owkin stock?

As Owkin is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Owkin, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Owkin stock?

To invest in a private company like Owkin through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Owkin stock?

Yes, you may sell the Owkin stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Owkin stock?

If you hold private company shares of Owkin – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Owkin on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Owkin a public company?

No, Owkin is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Owkin’s stock price?

Owkin is a privately held company and therefore does not have a public stock price. However, you may access Owkin private market stock price with Forge Data.
plusminus

What is Owkin’s stock ticker symbol?

Owkin does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Owkin’s news and media highlights

TechBio firm Owkin will use Amazon Web Services' cloud infrastructure and services to develop generative AI applications for drug discovery and healthcare. This collaboration aims to accelerate innovation in the healthcare sector by leveraging AWS's storage, security, computing capabilities, and Owkin's AI expertise.
Executives from French AI company Owkin are launching a new startup, Bioptimus, to build a large language model for biotechnology that will enhance Owkin's existing AI for drug discovery.
Paris-based VC firm Frst has closed €72m of its third fund, with investors including the European Investment Fund, Bpifrance, Axa Venture Partners, Isomer and Mubadala. The firm plans to invest the capital over four years into 30 seed-stage companies across various sectors, with investments ranging between €1m-3m. Frst aims to close the fund at €100m and is seeking more sovereign wealth funds, fund-of-funds and asset managers to invest.
Owkin, an AI biotech company, has invested $50 million in a project using spatial omics to revolutionize cancer research. The project, named MOSAIC, will be conducted in collaboration with Nanostring Technologies and several leading cancer research institutions. Spatial omics allows researchers to examine tumors at near single-cell resolution, providing a detailed map of molecular interactions. The project aims to unlock the next wave of treatments for difficult-to-treat cancers.
Updated on: Oct 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.